Elidel

Elidel 10g (Pimecrolimus) is a topical cream used to treat mild-to-moderate eczema (atopic dermatitis). This medication is prescribed in people who have not responded well to other eczema medications. It belongs to a class of drugs known as topical calcineurin inhibitors. This medicine may also be used to treat other conditions as determined by your doctor.

Product dosage: 10mg
Package (num)	Per tube	Price	Buy
1	$50.00	$50.00 (0%)	🛒 Add to cart
2	$45.00	$100.00 $90.00 (10%)	🛒 Add to cart
3	$40.00	$150.00 $120.00 (20%)	🛒 Add to cart
4	$37.50	$200.00 $150.00 (25%)	🛒 Add to cart
5	$34.00	$250.00 $170.00 (32%)	🛒 Add to cart
6	$30.00	$300.00 $180.00 (40%)	🛒 Add to cart
7	$27.14	$350.00 $190.00 (46%)	🛒 Add to cart
8	$25.00	$400.00 $200.00 (50%)	🛒 Add to cart
9	$23.33	$450.00 $210.00 (53%)	🛒 Add to cart
10	$22.00 Best per tube	$500.00 $220.00 (56%)	🛒 Add to cart
Synonyms Pacroma

Elidel (pimecrolimus) cream 1% is a non-steroidal topical immunomodulator specifically formulated for the short-term and intermittent long-term treatment of mild to moderate atopic dermatitis (eczema) in non-immunocompromised patients aged 2 years and older. It represents a significant advancement in dermatological therapy by selectively targeting inflammatory pathways at the site of application, offering a precise mechanism of action that minimizes systemic exposure. This prescription medication is indicated for use when conventional therapies are deemed inadvisable, or if the patient is not responsive to or intolerant of such treatments. By inhibiting T-cell activation and the release of pro-inflammatory cytokines, Elidel provides effective control of eczema symptoms, including pruritus and erythema, without the potential side effects associated with prolonged corticosteroid use, such as skin atrophy.

Features

• Contains 1% pimecrolimus as the active pharmaceutical ingredient.
• Available in 30g, 60g, and 100g tubes.
• A white, homogeneous cream for topical application only.
• A non-steroidal, calcineurin inhibitor (TCI) class medication.
• Designed for selective inhibition of inflammatory cytokines.
• Formulated for minimal systemic absorption when applied to the skin.

Benefits

• Provides rapid relief from the intense itching and inflammation associated with eczema flare-ups.
• Offers a steroid-free treatment option, eliminating concerns about skin thinning, striae, or tachyphylaxis associated with long-term topical corticosteroid use.
• Enables proactive management at the earliest signs of eczema (e.g., itching, redness) to help prevent full-blown flares.
• Suitable for sensitive skin areas, including the face, neck, and skinfold areas, where corticosteroids are often avoided.
• Supports long-term disease control with intermittent use, helping to maintain periods of clear skin.
• Helps restore the skin’s barrier function by effectively controlling underlying inflammation.

Common use

Elidel cream is primarily prescribed for the management of mild to moderate atopic dermatitis. It is used on affected areas of the skin to reduce the signs and symptoms of the condition, most notably pruritus (itching) and erythema (redness). Its application is recommended at the first appearance of signs and symptoms to prevent the progression of a flare. It is particularly valuable for use on delicate areas such as the face and eyelids, where the risks of topical steroid side effects are higher. Treatment should be initiated twice daily and continued until symptoms clear. It is not intended for continuous, long-term daily use but rather for intermittent management of acute flares and subsequent proactive therapy.

Dosage and direction

A thin layer of Elidel cream 1% should be applied to the affected area twice daily. The cream should be rubbed in gently and completely. Treatment should be started at the first signs or symptoms of atopic dermatitis (e.g., itching, redness). It is important to use the smallest amount needed to control symptoms. Hands should be washed thoroughly with soap and water after application if the hands are not the area being treated. Treatment should continue until signs and symptoms (itching, rash, redness) resolve. If signs and symptoms persist beyond 6 weeks, the patient should be re-evaluated.

Precautions

Elidel may be associated with an increased risk of skin infections, including eczema herpeticum. If a skin infection is present or develops, use should be discontinued until the infection has been adequately treated. Patients should minimize exposure to natural and artificial sunlight (tanning beds, UVA/B treatment) during treatment. Protective clothing and broad-spectrum sunscreen should be used on treated areas when sun exposure cannot be avoided. The effect of Elidel on immune system development in children is not fully known; therefore, long-term safety has not been established. It should not be used with occlusive dressings. Application to potentially malignant or pre-malignant skin conditions should be avoided.

Contraindications

Elidel is contraindicated in patients with a known hypersensitivity to pimecrolimus or any other component of the cream. It should not be used in patients with Netherton’s syndrome or other skin diseases where there is a potential for significantly increased systemic absorption of the drug. Its use is also contraindicated in individuals with congenital or acquired immunodeficiencies, or in those receiving immunosuppressive therapy, due to the potential increased risk of infections and malignancies.

Possible side effect

The most common side effects are application site reactions, including burning, warmth, or stinging sensation, which typically occur during the first few days of application and usually lessen as the skin heals. Other common side effects include headache, cough, and symptoms of the common cold. Less frequently, patients may experience folliculitis, acne, herpes simplex infections (cold sores), varicella (chickenpox), or increased sensitivity to hot or cold temperatures. Although rare, there is a boxed warning for a potential increased risk of skin malignancies and lymphoma; patients should be monitored for any unusual skin changes.

Drug interaction

Formal drug interaction studies with Elidel have not been conducted. Due to its low systemic absorption, systemic drug interactions are considered unlikely. However, caution is advised when using Elidel concomitantly with other topical preparations, especially those that may enhance skin absorption or cause local irritation (e.g., corticosteroids, retinoids, abrasive medicated soaps). Concurrent use with other immunosuppressive agents could theoretically increase overall immunosuppression.

Missed dose

If a dose is missed, it should be applied as soon as it is remembered. However, if it is almost time for the next scheduled application, the missed dose should be skipped, and the regular dosing schedule resumed. The patient should not apply a double dose to make up for the missed one.

Overdose

Acute overdose from topical application is unlikely due to minimal systemic absorption. However, excessive application could potentially lead to increased systemic exposure and an increased risk of the drug’s pharmacologic effects, primarily immunosuppression. There is no specific antidote for pimecrolimus overdose. Treatment should be supportive and symptomatic. In case of accidental ingestion, medical attention should be sought immediately.

Storage

Elidel cream should be stored at room temperature, between 15°C and 30°C (59°F and 86°F). The tube should be kept tightly closed when not in use. Do not freeze. Keep out of reach of children and pets. The medication should be discarded after the expiration date printed on the tube.

Disclaimer

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition or before starting any new treatment. Never disregard professional medical advice or delay in seeking it because of something you have read here.

Reviews

• “As a dermatologist, Elidel is a cornerstone in my toolkit for managing facial eczema in adult patients. It provides effective anti-inflammatory action without the risk of perioral dermatitis or skin atrophy that I worry about with steroids. Patients appreciate the rapid relief from itching.” – Dr. A. Reynolds, MD, Dermatology.
• “Managing my child’s eczema on his cheeks was a constant battle until our pediatrician prescribed Elidel. We use it at the first sign of pinkness, and it stops a full flare in its tracks. It’s been a game-changer for our family’s quality of life.” – Parent of a 5-year-old patient.
• “The initial burning sensation was a bit concerning, but my clinician prepared me for it. It subsided after a couple of days, and the cream worked incredibly well to clear a stubborn patch on my eyelid where I couldn’t use steroids.” – Patient, 42.
• “From a clinical perspective, the ability to use Elidel proactively has revolutionized how we approach eczema maintenance. Teaching patients to treat early signs, rather than waiting for a severe flare, leads to better long-term control and less overall medication use.” – Nurse Practitioner, Allergy & Immunology.
• “I’ve found it to be most effective for mild, superficial flares. For more lichenified, chronic plaques, I often need to initiate treatment with a potent steroid first and then use Elidel for maintenance to prevent rebound.” – Dr. L. Chen, Dermatologist.